GpharmaBioRESEARCH PEPTIDE LAB
Catalogue
GpharmaBioBPC-1575 mg · 3 mL · LYOLOT GPB-4471RUO

Purity

99.1%

Fill

5 mg

Vial

3 mL

Lot

GPB-4471

Repair · CAS 137525-51-0

BPC-157

Body Protection Compound 157

48.60per 5 mg · 3 mL vial · ex-VATRequest this lot’s COA

A fifteen-residue partial sequence of human gastric juice protein, synthesised by Fmoc SPPS and purified to a single dominant peak.

BPC-157 is our highest-volume reference peptide and the one most often ordered against a published protocol. Each batch is assembled by Fmoc solid-phase synthesis on Wang resin, cleaved with a TFA scavenger cocktail, and purified over a C18 column with a 0.1% TFA / acetonitrile gradient. We collect only the apex fraction — the shoulders go to waste rather than into your vial, which is why our yield per synthesis is lower than the trade average and our area-percent is higher. Residual solvent is driven off over a 34-hour lyophilisation cycle, and the cake is sealed under argon in 3 mL borosilicate before crimping.

Primary sequence

GlyGluProProProGlyLysProAlaAspAspAlaGlyLeuVal

Physical data

Molecular formula
C₆₂H₉₈N₁₆O₂₂
Molecular weight
1419.53 g/mol
CAS number
137525-51-0
Appearance
White to off-white lyophilised cake
Solubility
Soluble in sterile water and 0.9% NaCl
Storage
Lyophilised: −20 °C, desiccated, protected from light

Certificate of analysis

Lot GPB-4471
RP-HPLC purity99.1% area @ 214 nm
Identity (ESI-MS)1419.6 [M+H]⁺, within 0.4 Da
Net peptide content82.4% (nitrogen determination)
Water (Karl Fischer)3.1%
Residual TFA0.19%
Bacterial endotoxin< 0.12 EU/mg (LAL)

Handling

  • Ships ambient with a phase-change pack; refrigerate on arrival.
  • Reconstituted solutions are stable ~21 days at 2–8 °C.
  • Avoid repeated freeze–thaw; aliquot before the first freeze.

For laboratory research use only. Not for human or veterinary consumption, diagnostic or therapeutic use. Supplied to qualified researchers at institutional addresses.